ABSK-041

N/A

Report date: 2023/05/22 10:17:10
NME

Base Information

Drug NameABSK-041
Drug Alias NameABSK-041
ClassificationSmall molecules
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulantsProgrammed death-ligand 1 blockers
TargetsProgrammed death-ligand 1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesABbisko Therapeutics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesABbisko Therapeutics Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A